drugset / Trial / NCT02146833
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
RandomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2014-05
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |